Fishtailing stocks: Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT -1.69%), Cardlytics, Inc. (NASDAQ:CDLX 11.13%), Danimer Scientific, Inc. (NYSE:DNMR 4.80%)

Technical analysis of these three Hot stocks (LIXT, CDLX, DNMR)
Lixte Biotechnology Holdings, Inc. a USA based Biotechnology Company, belongs to a Healthcare Sector.
Cardlytics, Inc. a USA based Internet Content & Information Company belongs to a Communication Services Sector.
Danimer Scientific, Inc. a USA based Specialty Chemicals Company, belongs to a Basic Materials Sector.
Why Traders should have a look on beta and why it is important
Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an predictable return higher than the risk-free rate of interest.
Now have a glance on “Beta value” of these three stocks
LIXT’s Beta value is -0.26, CDLX’s Beta value is 1.78, DNMR’s Beta value is 0.
On 01-17-2k23 (Tuesday), Shares of Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) encountered a difference of -1.69% after which it shut the day’ session at $1.16. The volume added 717,208 shares which compares with the average volume of 1.27M shares.
Lixte Biotechnology Holdings, Inc., a USA based Company, belongs to Biotechnology sector industry. Shares of Lixte Biotechnology Holdings, Inc. was among the active stocks of the last exchanging sessions.
Unpredictability:
The stock value instability stayed at 26.42% in recent month and ranges at 28.03% for the week. The Average True Range (ATR) is also a measure of volatility is presently sitting at 0.26. The firm demonstrates the market capitalization of $17.49M.
Important Results:
Lixte Biotechnology Holdings, Inc. has P/S value of 0 while its P/B esteem remains at 6.82. Likewise, the company has Return on Assets of -8.50%, Return on Equity of -328.70% and Return on Investment of 0.
The company demonstrates Gross Margin and Operating Margin of 0 and 0 respectively.
Forward P/E of Lixte Biotechnology Holdings, Inc. is remaining at 0. Forward P/E is a measure of the price-to-earnings ratio using forecasted earnings for the P/E calculation for the next fiscal year.
Technical Analysis of Lixte Biotechnology Holdings, Inc. LIXT:
The stock price moved with change of 152.72% to its 50 Day low spot and changed -57.04% contrasting with its 50 Day high point. LIXT stock is as of now appearing down return of -7.94% all through a week ago and saw bearish return of 106.77% in one month span. The execution of company 107.14% in three months and 44.28% throughout the previous a half year exchanging period.
Tracking the closing price and 52-week high, the current price movement shows that the stock price positioned negative when compared against the 52-week high. As close of recent trade, stock represents -76.57%move from 52-week high. Tracing the 52-week low position of the stock, we noted that the closing price represents a 168.52% higher distance from that low value. Technical analysts compare a stock’s current trading price to its 52-week range to get a broad sense of how the stock is doing, as well as how much the stock’s price has fluctuated. This information may indicate the potential future range of the stock and how volatile the shares are.
Cardlytics, Inc. (NASDAQ:CDLX)’s Analysis & Performances to Discover
Cardlytics, Inc., belongs to Communication Services sector and Internet Content & Information industry. The company’s total Outstanding Shares of 32.95M. CDLX flaunted 11.13% to reach at $7.29 during previous trading session.
The company has experienced volume of 588,168 shares while on average the company has a capacity of trading 701.96K share.
Observing the Technical Indicators:
Cardlytics, Inc. institutional ownership is held at 95.80% while insider ownership was 2.10%. As of now, CDLX has a P/S, P/E and P/B values of 0.84, 0 and 0.41 respectively. Its P/Cash is valued at 1.86.
The Company’s net profit margin for the 12 months at -32.30%. Comparatively, the gazes have a Gross margin 48.20%.
Profitability ratios:
Looking into the profitability ratios of CDLX stock, an investor will find its ROE, ROA, ROI standing at -15.50%, -8.50% and -13.10%, respectively.
Reading RSI Indicator
Cardlytics, Inc. (CDLX) attained alert from day Traders as RSI reading reached at 56.81. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements.
Earnings per Share Details of Cardlytics, Inc.:
The EPS of CDLX is strolling at -3.03, measuring its EPS growth this year at -96.00%. As a result, the company has an EPS growth of 8.30% for the approaching year.
Danimer Scientific, Inc. (DNMR)’s Analysis & Performances to Discover

Further, 0.40% shares of Danimer Scientific, Inc. (NYSE:DNMR) are owned by insiders with -36.32% six-month change in the insider ownership. The insider filler data counts the number of monthly positions over 3 month and 12 month time spans. The stock closed at $2.40 by scoring 4.80%. Short-term as well long term investors always focus on the liquidity of the stocks so for that concern, liquidity measure in recent quarter results of the company was recorded 5.20 as current ratio and on the opponent side the debt to equity ratio was 0.73 and long-term debt to equity ratio also remained 0.73. The stock showed monthly performance of 7.62%. Likewise, the performance for the quarter was recorded as -14.89% and for the year was -89.18%.
Growth in earnings per share is everything. The expected future growth in earnings per share (“EPS”) is an incredibly important factor .in identifying an under-valued stock. The impact of earnings growth is exponential. Over the long run, the price of a stock will generally go up in lock step with its earnings (assuming the P/E ratio is constant). Therefore stocks with higher earnings growth should offer the highest capital gains. And doubling the growth more than doubles the capital gain, due to the compounding effect.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -1.62 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 34.08%.
Danimer Scientific, Inc. (NYSE:DNMR) exchanged hands 689,404 shares versus average trading capacity of 1.23M shares, while its relative trading volume is 0.55. DNMR’s total market worth is $247.58M. The Company has a Return on Assets of -20.70%. The company currently has a Return on Equity of -35.50% and Return on Investment of -11.40%.

Danimer Scientific, Inc. (NYSE:DNMR) reached at $2.40 price level during last trade its distance from 20 days simple moving average is 2.65%, and its distance from 50 days simple moving average is 16.03% while it has a distance of -29.89% from the 200 days simple moving average. The company’s distance from 52-week high price is -64.58% and current price is above +52.87% from 52-week low price.
What Does the Payout Ratio Tell You?
The payout ratio is a key financial metric used to determine the sustainability of a company’s dividend payments. It is the amount of dividends paid to shareholders relative to the total net income of a company.
Formula for the Payout Ratio Is
“Payout Ratio = Dividends / Earnings”
Is It Overvalued? Look at the Payout Ratio of LIXT, CDLX,DNMR
The payout ratio shows the proportion of earnings paid out as dividends to shareholders, typically expressed as a percentage of the company’s earnings. The payout ratio can also be expressed as dividends paid out as a proportion of cash flow. The payout ratio is also known as the dividend payout ratio. LIXT has a Payout Ratio of 0 and CDLX has a Payout Ratio of 0. DNMR has a Payout Ratio of 0.00%.

The post Fishtailing stocks: Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT -1.69%), Cardlytics, Inc. (NASDAQ:CDLX 11.13%), Danimer Scientific, Inc. (NYSE:DNMR 4.80%) appeared first on Stocks Equity.

stocks
shares
index
trading
nasdaq
healthcare